Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
about
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary diseaseβ(2) -adrenoceptor agonists: current and future directionA rational approach to single, dual and triple therapy in COPDImproving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterolChronic obstructive pulmonary diseaseInhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled dataEfficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysisPredicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease.Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysisOlodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigsSafety of indacaterol in the treatment of patients with COPD.Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis.Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.Indacaterol (arcapta neohaler) for chronic obstructive pulmonary diseaseEffect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trialIndacaterol in chronic obstructive pulmonary disease: an update for clinicians.Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease.Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach.Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.Chronic obstructive pulmonary disease in China: the potential role of indacaterolEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyIndacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.An update on the use of indacaterol in patients with COPD.Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.Indacaterol: a novel long-acting β(2) -agonist.Future of chronic obstructive pulmonary disease management.A review of the advances in chronic obstructive pulmonary disease treatment.Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
P2860
Q24186652-4FD3A468-447A-45A5-A19C-1E74F50A0092Q24604047-024F18B4-3551-4D8D-B33C-52428A4A10E6Q26776477-5B5FADF0-2230-4514-96A4-94CD702B0E68Q26851664-A71E8794-0227-4643-BBA0-9525569E00CCQ27027955-22652ADE-FBBC-4235-9046-861484750AECQ33766481-375526C5-CF47-41DC-9A61-0BA5655C2786Q34011640-52FCB735-7FC3-4771-91A7-971E5C980C21Q34049219-299006AC-69F6-4D67-9F5B-E654AA35B8C8Q34316776-16CBE451-2906-4982-9105-0E5988BDC54BQ34322908-717119E2-005E-4023-B7DE-F81433548B09Q34544020-D08EC856-A19E-4D35-9673-9E71D60447BCQ34962838-83A81397-1231-4CF6-98C0-F68191E84B12Q35190258-248B6A7F-80EC-4071-B556-DFB93A407ACBQ35268351-0A5762AF-71B7-4E1D-AC86-DF98E85207FCQ35589191-45518EB6-3AD5-46DB-B726-7A2B3221A13DQ35778149-8016FDFE-81A5-41D3-82DB-6448B237CA92Q35782210-0AD001EB-208C-45B9-AD12-64183B4B2FECQ35822146-5917EC2D-164C-4FC8-B915-DCF98D4B9847Q35958673-88B1A19B-1DC5-4592-85B9-A026FC3DDEC7Q36072399-45490804-A922-452A-92E4-883564DCE2C2Q36443777-285FDDE1-127C-49BA-B025-6BFEC18CDED9Q36500425-7EF173B6-9A91-47CE-9BE0-0F6A56C7B797Q36579746-C985F9CE-0F45-4967-A773-46FB10E0C359Q36924015-81F64644-A5C2-4F6E-A56F-D1BDDC5829D1Q37128034-D52A9064-5506-48DD-A543-5CE2BA0EE432Q37247499-A3D3AF5F-05AD-4418-BF0E-68981059EF38Q37390507-7B8F85C8-AC6C-43F4-ABC6-BBCA8C717D6AQ37603579-7BC4A826-15AE-4E0B-AF21-B8C8949E8B08Q37804908-0F313EFE-FBF6-4245-85DD-4369A4959B5EQ37808058-BF3F12C3-8F59-44A6-B8D9-5F273A4AE500Q37846698-88959FE2-11F5-4F4D-9573-24DF9BF86214Q37893470-FCEC0E3C-B9AB-4D28-A75B-EA5122C82288Q37896372-D26C6910-F6A7-4517-A67F-464E6391EEA3Q37911291-BBE86333-4627-424E-BC86-2A2DADFCBEE6Q37987211-7491EA12-8CD0-4584-AD78-A739C590F2D4Q37999465-0A8CD7EF-D1CC-486A-B823-5835A7453001Q38002357-616E71BB-B857-4E64-9318-E435FB4EA638Q38025725-10BDDBDA-2763-457C-BDE3-10E3F491F6FDQ38053126-87346032-0997-43AF-BFDE-A8D8A9650693Q38148145-4D7E853B-19A2-41B4-8877-D19A73EA24A0
P2860
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@ast
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en-gb
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@nl
type
label
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@ast
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en-gb
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@nl
altLabel
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en
prefLabel
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@ast
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en-gb
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@nl
P2093
P2860
P3181
P356
P1476
Efficacy and safety of indacat ...... ind, randomised, 12-week study
@en
P2093
Benjamin Kramer
Damon Jack
Gregory Feldman
Mark Higgins
Niyati Prasad
Roger Owen
Simon Piggott
Thomas Siler
P2860
P2888
P3181
P356
10.1186/1471-2466-10-11
P407
P577
2010-01-01T00:00:00Z
P5875
P6179
1013043550